Bortezomib

Multiple Myeloma, Mantle Cell Lymphoma
Treatment
4 FDA approvals
20 Active Studies for Bortezomib

What is Bortezomib

BortezomibThe Generic name of this drug
Treatment SummaryBortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma.[A204083] The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib.[L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083] Bortezomib was first synthesized in 1995.[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE.[A204146] Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.[A214307]
Velcadeis the brand name
image of different drug pills on a surface
Bortezomib Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Velcade
Bortezomib
2003
29

Approved as Treatment by the FDA

Bortezomib, commonly known as Velcade, is approved by the FDA for 4 uses like Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM) .
Mantle Cell Lymphoma (MCL)
Multiple Myeloma (MM)
Mantle Cell Lymphoma
Multiple Myeloma

When to interrupt dosage

The suggested dosage of Bortezomib is contingent upon the diagnosed condition. The dose will vary, in accordance with the mode of delivery outlined in the table below.
Condition
Dosage
Administration
Multiple Myeloma
, 3.5 mg, 1.0 mg, 2.5 mg, 1.0 mg/mL, 3.0 mg
, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intravenous; Subcutaneous, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Subcutaneous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous
Mantle Cell Lymphoma
, 3.5 mg, 1.0 mg, 2.5 mg, 1.0 mg/mL, 3.0 mg
, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intravenous; Subcutaneous, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Subcutaneous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Warnings

Bortezomib Contraindications
Condition
Risk Level
Notes
intrathecal administration
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Bortezomib may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Bortezomib may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Bortezomib may interact with Pulse Frequency
There are 20 known major drug interactions with Bortezomib.
Common Bortezomib Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Bortezomib is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Bortezomib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Bortezomib is combined with Abetimus.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Bortezomib.
Acteoside
Major
The risk or severity of adverse effects can be increased when Bortezomib is combined with Acteoside.
image of a doctor in a lab doing drug, clinical research

Bortezomib Novel Uses: Which Conditions Have a Clinical Trial Featuring Bortezomib?

Currently, there are zero active trials examining the potential of Bortezomib to be used in the treatment of undefined conditions.
Condition
Clinical Trials
Trial Phases
Multiple Myeloma
6 Actively Recruiting
Phase 1, Phase 2
Mantle Cell Lymphoma
72 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1

Bortezomib Reviews: What are patients saying about Bortezomib?

5Patient Review
10/1/2007
Bortezomib for Multiple Myeloma
5Patient Review
7/17/2015
Bortezomib for Mantle Cell Lymphoma
4Patient Review
12/13/2016
Bortezomib for Multiple Myeloma
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about bortezomib

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What drug class is bortezomib?

"Bortezomib is a type of medication that helps to kill cancer cells. This medication is known as an antineoplastic agent."

Answered by AI

Is bortezomib a immunotherapy?

"The findings from this study predict that bortezomib has the potential to be a safe and effective immunotherapy drug when used in conjunction with other immune therapies."

Answered by AI

Is bortezomib a chemotherapy drug?

"Vercade (bortezomib) is a targeted chemotherapy that inhibits the proteasome. It is approved by the FDA to treat multiple myeloma and mantle cell lymphoma. Vercade has shown to be effective in many clinical trials."

Answered by AI

What is bortezomib mechanism of action?

"The mechanism of action for Bortezomib is that it inhibits the 26S proteasome, which then prevents the activation of NF-κB. Bortezomib induces apoptosis in cells that are rapidly dividing and are active in synthesizing proteins."

Answered by AI

Clinical Trials for Bortezomib

Image of Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center in Cleveland, United States.

Rituximab + Tafasitamab + NK Cells for Non-Hodgkin's Lymphoma

18+
All Sexes
Cleveland, OH
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death). Participants in this study will receive lymphodepleting chemotherapy, as well as Allogeneic NK cells, Tafasitamab and Interleukin-2 (IL-2) by an intravenous (IV) infusion. Participants are expected to complete one cycle, and they may be eligible to complete a second cycle of the same regiment if they have stable disease, partial or complete remission at the end of the first cycle. Participants will be in this study for about 12 months.
Phase 1
Waitlist Available
Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center (+1 Sites)Paolo Caimi, MDIncyte Corporation
Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Sonrotoclax + Rituximab + Zanubrutinib for Lymphoma

18+
All Sexes
Seattle, WA
This phase II trial studies the side effects of an escalated ramp-up of sonrotoclax following initial debulking with zanubrutinib or rituximab in treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) that is newly diagnosed, has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Rituximab is a monoclonal antibody that binds to a protein called CD20, which is found on B-cells, and may kill tumor cells. Zanubrutinib may stop the growth of tumor cells by blocking a protein called Bruton's tyrosine kinase (BTK), which is needed for tumor cell growth. Sonrotoclax works by blocking a protein called B-cell lymphoma-2 (BCL-2). This protein helps certain types of blood tumor cells to survive and grow. When sonrotoclax blocks Bcl-2 it slows down or stops the growth of tumor cells and helps them die. Giving an increased dose of sonrotoclax over a shorter period of time in combination with zanubrutinib or rituximab may be safe and tolerable in treating patients with newly diagnosed, relapsed or refractory CLL, SLL, and MCL.
Phase 2
Recruiting
Fred Hutch/University of Washington Cancer ConsortiumMazyar Shadman, MD, MPHBeiGene
Have you considered Bortezomib clinical trials? We made a collection of clinical trials featuring Bortezomib, we think they might fit your search criteria.Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

Nemtabrutinib + Rituximab for Mantle Cell Lymphoma

18+
All Sexes
Duarte, CA
This phase II trial tests how well nemtabrutinib works with rituximab for the treatment of patients with mantle cell lymphoma. Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nemtabrutinib with rituximab may kill more cancer cells in patients with mantle cell lymphoma.
Phase 2
Recruiting
City of Hope Medical Center (+1 Sites)Alexey V Danilov
Have you considered Bortezomib clinical trials? We made a collection of clinical trials featuring Bortezomib, we think they might fit your search criteria.Go to Trials
Image of OHSU Knight Cancer Institute in Portland, United States.

Glofitamab + Ibrutinib + Obinutuzumab for Mantle Cell Lymphoma

18+
All Sexes
Portland, OR
This phase IB/II trial tests the safety, side effects and effectiveness of glofitamab plus ibrutinib with obinutuzumab for the treatment of patients with mantle cell lymphoma (MCL). Glofitamab is in a class of medications called bispecific monoclonal antibodies. It works by killing cancer cells. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). In the body, glofitamab binds to a receptor called CD3 on T-cells (a type of immune cells) and a receptor called CD20 on B-cells, a receptor that is often over-expressed on the surface of cancerous B-cells. When glofitamab binds to CD3 and CD20 receptors, it causes an immune response against the CD20-expressing cancerous B-cells. Ibrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Glofitamab plus ibrutinib with obinutuzumab may be safe tolerable and/or effective in treating patients with MCL.
Phase 1 & 2
Waitlist Available
OHSU Knight Cancer InstituteStephen E SpurgeonGenentech, Inc.
Image of University of California, San Francisco in San Francisco, United States.

Glofitamab + Pirtobrutinib for Mantle Cell Lymphoma

18+
All Sexes
San Francisco, CA
This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Obinutuzumab may also reduce the risk of immune-related conditions from treatment. Pirtobrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the protein that signals cancer cells to multiply. Giving glofitamab in combination with pirtobrutinib may be safe, tolerable and/or effective in treating patients with relapsed or refractory mantle cell lymphoma.
Phase 2
Recruiting
University of California, San Francisco (+1 Sites)Madhav Seshadri, MDGenentech, Inc.
Have you considered Bortezomib clinical trials? We made a collection of clinical trials featuring Bortezomib, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security